Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

G1 Therapeutics Inc (NQ: GTHX )

1.840 -0.160 (-8.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 513,060
Open 2.020
Bid (Size) 1.810 (60)
Ask (Size) 1.890 (17)
Prev. Close 2.000
Today's Range 1.810 - 2.020
52wk Range 1.080 - 8.400
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
From G1 Therapeutics
Via GlobeNewswire

Performance

YTD
-67.89%
-67.89%
1 Month
+13.58%
+13.58%
3 Month
+8.24%
+8.24%
6 Month
-34.29%
-34.29%
1 Year
-70.18%
-70.18%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Earnings Preview For G1 Therapeutics
Via Benzinga
Analyst Ratings for G1 Therapeutics
Via Benzinga
Analyst Ratings for G1 Therapeutics
Via Benzinga
Where G1 Therapeutics Stands With Analysts
Via Benzinga
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
From G1 Therapeutics
Via GlobeNewswire
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
From G1 Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
From G1 Therapeutics
Via GlobeNewswire
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
From G1 Therapeutics
Via GlobeNewswire
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 9, 2023: BABA, TSM, LCID, H, GTHX
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.